Article
TP53 Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study.
Annals of laboratory medicine - 1 Mar 2025
Kim Hyun-Young, Shin Saeam, Lee Jong-Mi, Kim In-Suk, Kim Boram, Kim Hee-Jin, Choi Yu Jeong, Bae Byunggyu, Kim Yonggoo, Ji Eunhui, Kim Hyerin, Kim Hyerim, Lee Jee-Soo, Chang Yoon Hwan, Kim Hyun Kyung, Lee Ja Young, Yu Shinae, Kim Miyoung, Cho Young-Uk, Jang Seongsoo, Kim Myungshin
Abstract excerpt
Background: TP53 mutations are associated with poor prognosis in myelodysplastic neoplasm (MDS) and AML. The updated 5th WHO classification and International Consensus Classification (ICC) categorize TP53-mutated MDS and AML as unique entities. We conducted a multicenter study in Korea to investigate the characteristics of TP53-mutated MDS and AML, focusing on diagnostic aspects based on updated classifications....
Read the complete abstract on PubMedTopics
- Humans
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Tumor Suppressor Protein p53